Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q1 2022 Earnings Presentation
12 slides from Adc Therapeutics Sa's earnings presentation, May 9, 2022
Slide 1: 1Q 2022 Earnings Call
1Q 2022 Earnings Call May 9, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Chris Martin Introduction Former Chief Executive Officer 02 Ameet Mallik Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 03 Chief Commercial Officer Joseph Camardo 04 Chief Medical Officer Clinical Highlights Jenn Creel 05 Chief Financial Officer Financial Update
Slide 4: CEO Transition from Chris Martin to Ameet Mallik
CEO Transition from Chris Martin to Ameet Mallik § Dr. Martin will serve as a non-executive member of the § Pharmaceutical industry veteran with deep oncology Board and Chair of the Science and Technology experience - 16 years in various leadership roles at Committee Novartis, including Executive Vi
Slide 5: Recent Highlights
Recent Highlights - Net sales: $16.5M in 1Q 2022 reflecting modest inventory build at end of Q4 2021 and fewer new DLBCL ZYNLONTA® patient starts in Q1, which was exacerbated by the Omicron surge; confident in ability to continue to grow (loncastuximab ZYNLONTA tesirine-lpyl) - Focused ZYNLONTA deve
Slide 6: ZYNLONTA Launch Dynamics
ZYNLONTA Launch Dynamics Encouraging ordering patterns: Increasing 3L+ market share: over 75% of accounts have with HCPs confirming reordered, over 96% of priority experience consistent with accounts and 94% of NCCN centers pivotal data have ordered Increasing 3L+ Encouraging market share ordering p
Slide 7: Focused ZYNLONTA Strategy
Focused ZYNLONTA Strategy LOTIS-9 1L DLBCL unfit/frail LOTIS-7 § Exploratory trial in combination with rituximab NHL § Expected initiation in 2H 2022 § Phase 1 trial of ZYNLONTA in multiple combinations LOTIS-6 § Expected initiation in 1H 2022 r/r FL § Pivotal Ph 2 trial of ZYNLONTA monotherapy in r
Slide 8: Cami Pivotal Phase 2 Trial in Hodgkin Lymphoma
Cami Pivotal Phase 2 Trial in Hodgkin Lymphoma Novel ADC targeting CD25 and regulatory T cells (Tregs) § Abstract of topline results submitted to an upcoming hematology conference § Preparing for pre-BLA meeting with FDA § Interim data presented at ICML 2021 demonstrating encouraging antitumor activ
Slide 9: Solid Tumor Franchise: Leveraging Validated ADC Platform
Solid Tumor Franchise: Leveraging Validated ADC Platform Cami § Targeting advanced solid tumors with evidence of CD25(+) Treg content Targeting CD25 § Phase 1b trial of Cami + pembrolizumab: Small dose expansion at the 60 ug/kg dosing level. Dose escalation continuing - currently at 100 µg/kg. Safet
Slide 10: 1Q 2022 Financial Update (in $ Millions)
1Q 2022 Financial Update (in $ Millions) Balance Sheet March 31, 2022 December 31, 2021 Cash and cash equivalents $430.9 $466.5 Statement of Cash Flows 1Q 2022 1Q 2021 Net cash used in operating activities $33.9 $55.1 Statement of Operations 1Q 2022 1Q 2021 Product Revenue, Net $16.5 N/A License Rev
Slide 11: Anticipated Development Milestones
Anticipated Development Milestones Hematology Programs ZYNLONTA: q 1H 2022: Initiate randomized portion of the LOTIS-5 confirmatory trial in combination with rituximab q 1H 2022: Initiate ZYNLONTA trial in multiple combinations in NHL q 2H 2022: Initiate LOTIS-9 trial of ZYNLONTA + rituximab in 1L u
Slide 12: 1Q 2022 Earnings Call
1Q 2022 Earnings Call THERAPEUTICS Innovating Science. Inspiring Hope.